For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Transmedics Group Inc (NASDAQ: TMDX) closed at $86.51 in the last session, up 2.79% from day before closing price of $84.16. In other words, the price has increased by $2.79 from its previous closing price. On the day, 0.6 million shares were traded. TMDX stock price reached its highest trading level at $86.72 during the session, while it also had its lowest trading level at $83.13.
Ratios:
We take a closer look at TMDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.49 and its Current Ratio is at 9.30. In the meantime, Its Debt-to-Equity ratio is 3.76 whereas as Long-Term Debt/Eq ratio is at 3.75.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on March 28, 2024, initiated with a Overweight rating and assigned the stock a target price of $95.
JP Morgan Upgraded its Neutral to Overweight on August 02, 2022, while the target price for the stock was maintained at $48.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 17 ’24 when Hassanein Waleed H sold 4,000 shares for $95.12 per share. The transaction valued at 380,480 led to the insider holds 74,087 shares of the business.
Hassanein Waleed H sold 12,000 shares of TMDX for $1,141,080 on Apr 10 ’24. The President & CEO now owns 74,087 shares after completing the transaction at $95.09 per share. On Apr 09 ’24, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 15,512 shares for $90.45 each. As a result, the insider received 1,403,082 and left with 25,185 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 2841966080 and an Enterprise Value of 2874455040. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.72 while its Price-to-Book (P/B) ratio in mrq is 20.60. Its current Enterprise Value per Revenue stands at 11.896 whereas that against EBITDA is 331.847.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $99.63, while it has fallen to a 52-week low of $36.42. The 50-Day Moving Average of the stock is 4.03%, while the 200-Day Moving Average is calculated to be 19.39%.
Shares Statistics:
According to the various share statistics, TMDX traded on average about 730.00K shares per day over the past 3-months and 924050 shares per day over the past 10 days. A total of 32.67M shares are outstanding, with a floating share count of 31.48M. Insiders hold about 3.79% of the company’s shares, while institutions hold 110.43% stake in the company. Shares short for TMDX as of 1711584000 were 5989785 with a Short Ratio of 8.21, compared to 1709164800 on 4983659. Therefore, it implies a Short% of Shares Outstanding of 5989785 and a Short% of Float of 21.180001.
Earnings Estimates
The current rating of Transmedics Group Inc (TMDX) is the result of assessments by The RBB Fund, Inc. Motley Fool analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $39.96, with high estimates of $0.02 and low estimates of $86.51.
